^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CDK4 inhibitor

    Related drugs:
    1d
    Cinderella-Neo: A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients. (clinicaltrials.gov)
    P2, N=42, Not yet recruiting, Fudan University
    New P2 trial
    |
    Perjeta (pertuzumab)
    3d
    FOURLIGHT-1: A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment (clinicaltrials.gov)
    P2, N=333, Active, not recruiting, Pfizer | Trial primary completion date: Sep 2025 --> Mar 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    everolimus • fulvestrant • exemestane • atirmociclib (PF-07220060)
    4d
    Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (clinicaltrials.gov)
    P3, N=701, Active, not recruiting, Celcuity Inc | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Jun 2026
    Enrollment closed • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    ER positive • PIK3CA mutation • PGR positive
    |
    Ibrance (palbociclib) • Piqray (alpelisib) • fulvestrant • gedatolisib (PF-05212384)
    4d
    Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial) (clinicaltrials.gov)
    P2, N=6, Terminated, M.D. Anderson Cancer Center | N=58 --> 6 | Trial completion date: Dec 2027 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2027 --> Dec 2025; <75% Participation
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    fulvestrant • Augtyro (repotrectinib)
    6d
    Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors (clinicaltrials.gov)
    P=N/A, N=100, Enrolling by invitation, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    10d
    FUTURE: Aspects of Adjuvant CDK4/6 Inhibitors in Older Breast Cancer Patients - Focusing on Geriatric Screening (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, Region Jönköping County
    New trial • HEOR
    14d
    ADELA: Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (clinicaltrials.gov)
    P3, N=240, Active, not recruiting, MedSIR | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 mutation
    |
    everolimus • Orserdu (elacestrant)
    15d
    Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 Inhibitor. (PubMed, J Med Chem)
    Central to our strategy were efficiency-based optimization (LipE and LipMetE), structure-based drug design, and molecular dynamics simulation. The culmination of these efforts resulted in the discovery of PF-07220060 (atirmociclib), which possessed high potency and levels of selectivity for CDK4 over CDK6 that translated to minimal impact on neutrophils while driving efficacy in a mouse ZR75-1 xenograft model.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDK6 (Cyclin-dependent kinase 6)
    |
    HR positive • HER-2 negative
    |
    atirmociclib (PF-07220060)
    17d
    Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC (clinicaltrials.gov)
    P2, N=14, Active, not recruiting, Case Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=29 --> 14
    Enrollment closed • Enrollment change
    |
    Verzenio (abemaciclib)
    17d
    Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Lucentis (ranibizumab) • Simponi (golimumab)
    21d
    A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants (clinicaltrials.gov)
    P1, N=35, Completed, Pfizer | Not yet recruiting --> Completed
    Trial completion
    |
    atirmociclib (PF-07220060)
    21d
    Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants (clinicaltrials.gov)
    P1, N=72, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    atirmociclib (PF-07220060)